BRCA1 and breast cancer: Given the fact that 6% of medical practitioners disagreed that BRCA1/2 gene screening is useful, even though it is a well-established clinical approach to breast cancer, it is encouraging that only 14% disagree with a PSGT approach (see responses in Supplementary Table S2).